When targeted therapies are used in combination with MCT1/2 inhibitor AZD3965 or LDHA inhibitor NHI-Glc-2, the sensitivity is restired in SLCLC and gastric cancer and they achieve more favorable efficacy.334 Lactate also induces resistance to pan-Akt inhibitor uprosertib in CRC. Here, SLC16A1 is linked to colorectal carcinoma.